"Unlimited cancer types" continued remission for more than 4 years!

In recent years, a major advancement in cancer precision medicine has been the "cancer-free" therapy.

In tropomyosin receptor kinase (TRK) fusion tumors, the NTRK gene is fused with an unrelated gene, resulting in the production of mutated TRK protein

Nearly 3 years after its approval, the long-term efficacy data of larotrectinib once again proved the benefits of this drug "without limitation of cancer types"! A number of studies were presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, including aggregated data on patients with 21 cancer types, as well as long-term data analysis for lung cancer and central nervous system (CNS) tumors

It is worth noting that the listing application of larotrectinib in China has also been included in the proposed priority review list by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for the treatment of adult and pediatric patients with solid tumors carrying NTRK fusion genes

Data collection of 21 cancer types: sustained remission for more than 4 years, 77% survived 3 years!

This is a comprehensive analysis of long-term follow-up data from 3 clinical trials

turn out:

75% of patients achieved objective remission (tumor volume reduction reached the predetermined value and can maintain the minimum time limit), including 45 cases (22%) complete remission, 109 cases (53%) partial remission; 33 cases (16%) disease Stable, disease progression in 13 cases (6%)

Treatment-related adverse events were mainly grade 1-2, 18% occurred grade 3-4, and only 2% of patients discontinued the drug due to treatment-related adverse events

These results emphasize the importance of detecting NTRK gene fusion in cancer patients, because most TRK fusion cancer patients treated with larotrectinib have long-term clinical benefits and no new safety signals have been discovered

Advanced lung cancer: median overall survival is more than 3 years, 73% achieve objective remission

As of July 20, 2020, the research team has aggregated data from 20 TRK fusion-positive lung cancer patients with a median age of 48.

turn out:

Among the 15 evaluable patients, 73% of patients achieved objective remission, 1 complete remission, 10 partial remission; 3 stable disease and 1 disease progression

Adverse events were mainly grade 1-2, 16 patients reported treatment-related adverse reactions, of which 2 cases had grade 3 events (myalgia, hypersensitivity, weight gain)

Larotrectinib has high activity, rapid and durable remission, prolonged survival benefit and good long-term safety characteristics in advanced lung cancer patients carrying NTRK gene fusion

CNS tumor patients: The median progression-free survival period is 18.

It was found that after receiving larotrectinib treatment:

The objective response rate for all patients was 30%: 3 pediatric patients had complete remission, 7 had partial remission (2 cases to be confirmed); 20 had stable disease (including 15 patients> 6 months), and 3 had disease progression

Twenty patients reported treatment-related adverse events, and 3 patients (9%) were grade 3-4

In patients with TRK fusion-positive central nervous system tumors, larotrectinib showed rapid and durable remission, high disease control rate and good safety characteristics
.
These results support the detection of NTRK gene fusion in patients with central nervous system tumors of all ages
.

Reference materials:

[1] Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
Retrieved June 8, 2021, from https://meetinglibrary.
asco.
org/record/195937/ abstract

[2] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
Retrieved June 8, 2021, from https://meetinglibrary.
asco.
org/record/195782/abstract

[3] Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Retrieved June 8, 2021, from https://meetinglibrary.
asco.
org/record/200553/abstract